CN116947999A

CN116947999A - Small molecular antibacterial polypeptide, preparation method and application thereof

Info

Publication number: CN116947999A
Application number: CN202310880462.6A
Authority: CN
Inventors: 占文虎; 周方行; 罗俊; 肖斌; 顾玲; 杨克树; 林全浩; 陈俊杰; 王维
Original assignee: Shenzhen Carbon Cloud Intelligent Peptide Pharmaceutical Technology Co ltd
Current assignee: Shenzhen Carbon Cloud Intelligent Peptide Pharmaceutical Technology Co ltd
Priority date: 2023-07-18
Filing date: 2023-07-18
Publication date: 2023-10-27
Also published as: WO2025015979A1

Abstract

The present invention relates to the technical field of antibacterial drugs, and in particular to small molecule antibacterial polypeptides, preparation methods and uses thereof. The antibacterial peptides provided by the present invention have stronger antibacterial activity than most other derived polypeptides and antibacterial polypeptides disclosed in existing reports. Bactericidal activity evaluation was carried out using a variety of bacterial strains known to have drug resistance. The results showed that the antibacterial peptide provided by the present invention has broad-spectrum antibacterial activity against drug-resistant strains, with a more comprehensive antibacterial effect and a wider range of indications.

Description

Small molecular antibacterial polypeptide, preparation method and application thereof

Technical Field

The application relates to the technical field of antibacterial drugs, in particular to a small molecular antibacterial polypeptide, a preparation method and application thereof.

Background

In recent decades, with the frequent and irregular use of antibiotics, the problem of bacterial resistance has become a public safety crisis. According to the latest investigation by the U.S. center for disease control and prevention (CDC), antibiotic resistance causes millions of people to develop disease annually, and it is expected that the number of deaths due to antibiotic resistance will reach tens of millions by 2050. Therefore, development of novel antibacterial agents has become urgent for anti-infective therapy.

Antimicrobial peptides (AMPs) have shown unprecedented advantages as promising antimicrobial agents against multidrug resistant bacteria. Unlike antibiotics, which interfere with the metabolic processes of pathogenic microorganisms, AMPs generally produce antimicrobial effects by physically disrupting microbial cell membrane lipids and inducing leakage of cell contents, so that their impact on the probability of evolution of bacterial resistance is small. AMPs are currently considered ideal candidates for replacing antibiotics due to their strong antibacterial potential and unique mechanism of action.

The Cathelicidin is a multifunctional antibacterial peptide family, has broad-spectrum antibacterial activity, has very strong bactericidal activity on gram-positive bacteria, gram-negative bacteria, certain fungi and viruses, and also has the same effect on a plurality of clinical drug-resistant bacteria. The antibacterial peptide (BF 30) is an active polypeptide separated from the snake venom of the Bungarus fasciatus in the 2008 academy of sciences, and the like, and is a single polypeptide drug containing 30 amino acids, which is obtained by artificial synthesis, is a linear polypeptide with alpha-helix at the N-terminal encoded by the gene of the Bungarus fasciatus Cathelicidin, contains 30 amino acid residues and has the molecular weight of 3636.24Da.

In view of the characteristics of high activity, difficult generation of drug resistance, wide action spectrum and the like of the bungarous mollis antibacterial peptide, the bungarous mollis antibacterial peptide becomes a very good lead molecule for screening novel anti-infective drugs, but the bungarous mollis antibacterial peptide BF30 has more complex sequence, high synthesis cost and antibacterial activity still needs to be improved.

Disclosure of Invention

The application aims at improving the activity of the bungaroid antibacterial peptide and reducing the synthesis cost of the bungaroid antibacterial peptide, and modifies and optimizes the nucleotide sequence and structure of the bungaroid antibacterial peptide to obtain the mutant antibacterial peptide with broad-spectrum high activity, and provides a preparation method and application of the mutant antibacterial peptide.

The first aspect of the present application provides an antibacterial peptide having the amino acid sequence VKRWKKFX ₁ X ₂ KWKKWV, wherein X ₁ And X ₂ Are each selected from amino acids having aromatic side chains or amino acids having basic side chains.

In an alternative embodiment, the X ₁ And X ₂ Respectively selected from phenylalanine or arginine.

In an alternative embodiment, the antimicrobial peptide has the amino acid sequence shown in SEQ ID NO.1 or 2.

In alternative embodiments, the N-terminus of the antimicrobial peptide contains a modifying functional group selected from the group consisting of 5-isoxazole-5-carbonyl, acetyl, 2- (1-imidazolyl) acetyl, benzoyl, decanoyl, 2-morpholinoacetyl, pyrazinyl, dodecanoyl, tosyl, or 2-methylthiazole-5-carbonyl.

In alternative embodiments, the modified antimicrobial peptide comprises at least one D-type or beta-type amino acid.

In a second aspect, the present application provides a method for preparing an antibacterial peptide according to any one of the preceding embodiments, wherein the method comprises coupling amino acids having side chain protecting groups sequentially according to amino acid sequences by solid phase synthesis or liquid phase synthesis, and sequentially removing the side chain protecting groups, extracting and purifying the amino acids to obtain the antibacterial peptide.

In an alternative embodiment, the method for preparing an antimicrobial peptide further comprises the step of performing N-terminal modification on the solid phase synthetic antimicrobial peptide, wherein the functional group used for the N-terminal modification is selected from 5-isoxazole-5 formyl, acetyl, 2- (1-imidazolyl) acetyl, benzoyl, decanyl, 2-morpholinoacetyl, pyrazinecarboxyl, dodecanoyl, p-toluenesulfonyl or 2-methylthiazole-5-formyl.

In alternative embodiments, at least one of the amino acids used in the solid phase synthesis is a D-type or β -type amino acid.

In a third aspect, the present application provides the use of an antimicrobial peptide according to any one of the preceding embodiments or an antimicrobial peptide obtained by the method according to any one of the preceding embodiments in the preparation of an antimicrobial drug, an anti-infective drug, a wound repair product, an acne treatment drug, a radiodermatitis control drug, a preservative, an animal feed or a cosmetic precursor.

In a fourth aspect, the present application provides an antibacterial pharmaceutical formulation comprising the antibacterial peptide according to any one of the preceding embodiments or prepared by the method according to any one of the preceding embodiments.

In an alternative embodiment, the effective dose of the antimicrobial peptide is between 0.01 and 516 μg/ml, preferably between 0.125 and 256 μg/ml.

In alternative embodiments, the pathogenic microorganism species of antimicrobial action include bacteria and/or fungi.

Preferably, the bacteria include gram positive bacteria such as staphylococcus aureus (Staphylococcus aureus) or enterococcus faecalis (Enterococcus faecalis); and/or gram-negative bacteria, such as Pseudomonas aeruginosa (Pseudomonas aeruginosa), escherichia coli (Escherichia coli), klebsiella pneumoniae (Klebsiella pneumoniae) or Acinetobacter baumannii (Acinetobacter baumannii).

In alternative embodiments, the pathogenic microorganism is resistant and the antibiotic resistant drug class includes at least one of beta-lactams, cephalosporins, aminoglycosides, macrolides, tetracyclines, fluoroquinolones, sulfonamides, or rifampin.

In alternative embodiments, the dosage form of the antibacterial pharmaceutical formulation includes an oral formulation, an external formulation or an injection; the oral preparation comprises granules, tablets, paste or oral solution; the external preparation comprises ointment, gel, suppository, medicated bath liquid, hoof bath liquid or spray.

The beneficial effects obtained by the application include:

compared with most other derived polypeptides and the antibacterial polypeptides disclosed in the prior reports, the antibacterial peptide provided by the application has stronger antibacterial activity. The antibacterial peptide provided by the application has broad-spectrum antibacterial activity on drug-resistant strains, and has more comprehensive antibacterial effect and wider applicable environment.

Furthermore, the safety of the antibacterial peptide provided by the application is evaluated by adopting hemolytic activity, and the preferable antibacterial peptide has no hemolytic toxicity at the highest concentration of 256 mug/ml and higher safety through measurement.

Therefore, the application provides the antibacterial peptide with stronger antibacterial activity, wider application range and larger potential value.

Drawings

FIG. 1 is a high performance liquid chromatogram of the antibacterial peptide WZ-1 synthesized in example 1;

FIG. 2 is a mass spectrum of the antibacterial peptide WZ-1 synthesized in example 1;

FIG. 3 is a high performance liquid chromatogram of the antibacterial peptide WZ-3 synthesized in example 2;

FIG. 4 is a mass spectrum of the antibacterial peptide WZ-3 synthesized in example 2;

FIG. 5 is a high performance liquid chromatogram of the antimicrobial peptide Ac-WZ-3 synthesized in example 3;

FIG. 6 is a mass spectrum of the antibacterial peptide Ac-WZ-3 synthesized in example 3;

FIG. 7 is a graph showing the results of experiments on the hemolytic activity of different antibacterial peptides provided by the application.

Detailed Description

In order to more clearly illustrate the embodiments of the present application or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly described, and it is apparent that the drawings in the description below are only one embodiment of the present application, and other embodiments may be obtained according to these drawings by those skilled in the art.

In the present application, unless otherwise indicated, scientific and technical terms used herein have the meanings commonly understood by one of ordinary skill in the art. Also, protein and nucleic acid chemistry, molecular biology, cell and tissue culture, microbiology, immunology-related terms and laboratory procedures as used herein are terms and conventional procedures that are widely used in the corresponding arts. Meanwhile, in order to better understand the present application, definitions and explanations of related terms are provided below.

It should also be understood that in some methods described herein that include more than one step or act, the order of the steps or acts of the method is not necessarily limited to the order in which the steps or acts of the method are recited, unless the context indicates otherwise.

Definition of the definition

As used herein, the terms "a" and "an" and "the" and similar referents refer to the singular and the plural, unless the context clearly dictates otherwise.

As used herein and unless otherwise indicated, the term "about" or "approximately" means within plus or minus 10% of a given value or range. In the case where an integer number is required, the term refers to integers rounded up or down to the nearest whole number within plus or minus 10% of a given value or range.

As used herein, the conjunctive term "and/or" between various of the elements is understood to each include a single option and a combined option. For example, when two elements are joined by an "and/or," the first option refers to the applicability of the first element without the second element. The second option refers to the applicability of the second element without the first element. The third option refers to the applicability of the first and second elements together. Any of these options is understood to fall within the meaning and therefore meets the requirements of the term "and/or" as used herein. Concurrent applicability of multiple options is also understood as the term's stated meaning, thus meeting the requirements of the term ' and/or '.

As used herein, the term "antimicrobial peptide", which may also be referred to as an "antimicrobial polypeptide", is synonymous with "antimicrobial protein", and is used herein to refer to a polymer of amino acid residues having antimicrobial, bacteriostatic or bactericidal functions. The term applies to amino acid polymers in which one or more amino acid residues are artificial chemical mimics of the corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers and non-naturally occurring amino acid polymers. Unless otherwise indicated, a particular polypeptide sequence also implicitly encompasses conservatively modified variants thereof.

As used herein, the term "drug resistance", also known as resistance, refers to the tolerance of microorganisms, parasites and tumor cells to the action of chemotherapeutic agents, which once developed, significantly reduces the chemotherapeutic action of the agent. Resistance can be classified into acquired resistance and natural resistance according to the cause of occurrence. Naturally occurring pathogens, such as a strain of bacteria, may also present natural resistance. When antibiotics are used for a long time, most sensitive strains are continuously killed, and drug-resistant strains are propagated in a large quantity to replace the sensitive strains, so that the drug-resistant rate of bacteria to the drug is continuously increased. The latter approach is currently considered to be the main cause of the development of drug-resistant bacteria. In order to maintain the effectiveness of the antibiotic, its rational use should be appreciated.

As used herein, the term "MRSA" refers to a drug resistant strain in the general sense of methicillin-resistant staphylococcus aureus. Has broad-spectrum drug resistance, is resistant to beta-lactam antibiotics and cephalosporin antibiotics, and can generate different degrees of drug resistance to aminoglycosides, macrolides, tetracyclines, fluoroquinolones, sulfonamides and rifampin (important for developing a key pathogen list for novel antibiotics of the world health organization).

As used herein, the term "MSSA" is methicillin-sensitive staphylococcus aureus.

As used herein, the term "D-amino acid", as opposed to an L-amino acid, is two isomers of the same amino acid having different optical activities. According to the fischer projection formula, the amino group is L-type amino acid on the left side, the amino group is D-type amino acid on the right side, usually the natural amino acid is L-type amino acid, and the D-type amino acid is obtained by artificial synthesis.

As used herein, the term "β -amino acid" refers to an amino acid whose amino group is bound to the carbon atom at the β -position. The only commonly occurring naturally occurring β -amino acid is β -alanine, which, although often as a constituent of biologically active macromolecules, is not generally found in nature. For this reason, β -peptide antibiotics are being used to address the problem of antibiotic resistance.

As used herein, the term "conservative substitutions" or "conservative sequence modifications" of a sequence, i.e., nucleotide and amino acid sequence modifications that do not eliminate the binding of an antibody encoded by or containing the nucleotide sequence to an antigen. These conservative sequence modifications include conservative nucleotide and amino acid substitutions, and nucleotide and amino acid additions and deletions. For example, modifications can be introduced into the sequence listing described herein by standard techniques known in the art, such as site-directed mutagenesis and PCR-mediated mutagenesis. Conservative sequence modifications include conservative amino acid substitutions in which an amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues with similar side chains are defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine), beta-branched side chains (e.g., threonine, valine, isoleucine), aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, the predicted nonessential amino acid residue in an anti-MASP-2 antibody is preferably replaced with another amino acid residue from the same side chain family. Methods for identifying nucleotide and amino acid conservative substitutions that do not eliminate antigen binding are well known in the art.

Exemplary amino acids that may be conservatively substituted are shown in Table 1 below:

table 1 amino acid conservative substitution examples

As used herein, the term "effective dose" is synonymous with "effective amount" and refers to an amount of a substance, compound, material, or composition comprising a compound that is at least sufficient to produce a therapeutic effect after administration to a subject. Thus, it is the amount necessary to prevent, cure, ameliorate, block or partially block the symptoms of a disease or disorder.

Detailed description of the preferred embodiments

In a first aspect the present application provides an antimicrobial peptide having the amino acid sequence X ₁ KRFKKFX ₂ X ₃ KLKKWV, wherein X ₁ Selected from nonpolar side chain amino acids, X ₂ Selected from amino acids having aromatic side chains, X ₃ Selected from amino acids having aromatic side chains or amino acids having basic side chains.

In an alternative embodiment, the X ₁ Selected from valine or isoleucine, said X ₂ Selected from phenylalanine or tryptophan, said X ₃ Selected from phenylalanine, tryptophan or arginine.

In an alternative embodiment, the antimicrobial peptide has the amino acid sequence shown in any one of SEQ ID NO. 1-2.

SEQ ID NO.1：VKRWKKFRFKWKKWV；

SEQ ID NO.2：VKRWKKFFRKWKKWV。

Wherein SEQ ID NO.2 is obtained by exchanging amino acids at positions 8 and 9 of SEQ ID NO.1, and the 8 th and 9 th positions after the exchange are subjected to non-conservative substitution. The amino acid sequences shown in SEQ ID NO.2 and SEQ ID NO.1 provided by the application contain 15 amino acid residues, 5 amino acid residues are taken as a fragment, and after the antibacterial peptide core fragment provided by the application is divided into three fragments from the N end to the C end, the amino acid sequences shown in SEQ ID NO.2 and SEQ ID NO.1 are polypeptide fragments with rich tryptophan at two ends and no tryptophan in the middle.

The modified functional group is a modified functional group added to the N-terminal of the antibacterial peptide for the purpose of improving the antibacterial activity of the antibacterial peptide, and it is understood that other conventional modified groups capable of improving the antibacterial peptide activity are also understood to be the scope of the present application.

In alternative embodiments, the modified antimicrobial peptide comprises at least one D-amino acid or beta-amino acid.

It is understood that polypeptide synthesis is a process of repeatedly adding amino acids. The solid phase synthesis sequence is generally synthesized from a C end (carboxyl end) to an N end (amino end), so that the difficulty of purifying the product in each step can be greatly reduced. To prevent side reactions, the side chains of the amino acids involved in the reaction are protected, the carboxyl terminus is free, and must be activated prior to the reaction. There are two methods of solid phase synthesis, fmoc and tBOC. The liquid phase synthesis mainly comprises two strategies of gradual synthesis and fragment combination, wherein the gradual synthesis is simple and rapid and is used for synthesizing various bioactive polypeptide fragments; the fragment combination method provides the most promising route for synthesizing the polypeptide containing more than 100 amino acids, and various bioactive polypeptides have been successfully synthesized, and the biggest characteristic is easy purification.

In an alternative embodiment, the preparation method of the antibacterial peptide further comprises a step of performing N-terminal modification on the solid-phase synthesis antibacterial peptide, wherein the functional group used for the N-terminal modification is selected from 5-isoxazole-5 formyl (Ez), acetyl (Ac), 2- (1-imidazolyl) acetyl (Mz), benzoyl (Bz), decacarbonyl (Dec), 2-morpholinoacetyl (Ml), pyrazinoyl (Pz), dodecanoyl (doc), tosyl (Ts) or 2-methylthiazole-5-formyl (Sz), and each functional group has the following structural formula:

in alternative embodiments, at least one of the amino acids used in the solid phase synthesis is a D-amino acid or a β -amino acid.

In a third aspect, the present application provides the use of an antimicrobial peptide according to any one of the preceding embodiments or obtained by the method of preparation according to any one of the preceding embodiments in the preparation of an antimicrobial drug, an anti-infective drug, a wound repair product, an acne treatment drug, a preservative, an animal feed or a cosmetic precursor.

In an alternative embodiment, the effective dose of the antimicrobial peptide is between 0.01 and 512. Mu.g/ml, preferably between 0.125 and 256. Mu.g/ml.

In alternative embodiments, the bacteria include gram positive bacteria, such as staphylococcus aureus (Staphylococcus aureus) or enterococcus faecalis (Enterococcus faecalis); and/or gram-negative bacteria, such as Pseudomonas aeruginosa (Pseudomonas aeruginosa), escherichia coli (Escherichia coli), klebsiella pneumoniae (Klebsiella pneumoniae) or Acinetobacter baumannii (Acinetobacter baumannii).

Embodiments of the present application will be described in detail below with reference to examples. It will be appreciated by those skilled in the art that the following examples are illustrative of the present application and should not be construed as limiting the scope of the application. The specific techniques or conditions are not identified in the examples and are performed according to techniques or conditions described in the literature in this field or according to the product specifications. The reagents or apparatus used were conventional products commercially available without the manufacturer's attention.

In the present application, the method of detection may be a method of detecting an antibacterial polypeptide, an antibacterial protein, which is conventional in the art, including but not limited to MIC assay, MBC assay, yield assay, purity assay, and hemolytic activity evaluation.

Exemplary:

the MIC determination method is as follows:

(1) Preparation of camdb medium: 22.5g of CAMHB culture medium powder (Shenzhen sea Bo biotechnology Co., ltd., product number: HB 6231-1) is weighed, 1000mL of distilled water is added, and the mixture is sterilized for later use; the CarMB culture medium contains beef extract powder and acid hydrolyzed casein, and can provide nitrogen source, vitamins and other growth factors required by bacterial growth; the contained soluble starch provides a carbon source and energy for bacteria; the calcium chloride can regulate pH and is also an activator of certain enzymes, and is commonly used for rapid enrichment culture of aerobic microorganisms in clinical samples or other samples.

(2) Sterilization of tools and instruments: placing the prepared CAMHB culture medium, 0.9% (w/v) NaCl, gun head and centrifuge tube into an autoclave at 121deg.C, and sterilizing for 30min. Drying the gun head, the centrifuge tube and the test tube in a drying box for 24 hours, and sterilizing the 96-well plate on an ultra-clean bench for 30 minutes by ultraviolet.

(3) Preparing a bacteriostatic polypeptide stock solution: the polypeptide samples were each prepared as 10mg/ml stock solution with sterilized 0.9% (w/v) NaCl. A maximum concentration of 512. Mu.g/ml was formulated with CAPMB medium and diluted to 256. Mu.g/ml, 128. Mu.g/ml, 64. Mu.g/ml, 32. Mu.g/ml, 16. Mu.g/ml, 8. Mu.g/ml, 4. Mu.g/ml, 2. Mu.g/ml, 1. Mu.g/ml, 0.5. Mu.g/ml, 0.25. Mu.g/ml depending on the system.

(4) Preparation of positive control drug: daptomycin (green leaf Biotechnology Co., ltd., B27420), BF-30 (Ji Er Biochemical Co., ltd., purity > 99%), ZY13 (Ji Biochemical Co., ltd., purity > 99%) were prepared by preparing mother solutions with sterile 0.9% (w/v) NaCl, respectively, and preparing the mother solutions with CAMHB medium to a maximum concentration of 512. Mu.g/ml, diluting to a concentration of 256. Mu.g/ml, 128. Mu.g/ml, 64. Mu.g/ml, 32. Mu.g/ml, 16. Mu.g/ml, 8. Mu.g/ml, 4. Mu.g/ml, 2. Mu.g/ml, 1. Mu.g/ml, 0.5. Mu.g/ml, 0.25. Mu.g/ml, respectively.

(5) Preparation of bacterial suspension: gram-negative bacteria were shaken in advance with LB (Siemens aerobe Co., ltd., 1278005) medium (lysis broth), gram-positive bacteria were shaken with TSB (Siemens aerobe Co., ltd., CM 0129) medium (tryptone soybean broth medium), 220rpm,37℃overnight, 1: diluted 1000 for use (final system concentration 1:2000 dilution).

(6) The specific operation steps are as follows

The first step: preparation and reagent preparation

Alcohol wiping on an operation table, preparing a gun head, a gun, an EP tube, a culture dish, a rack, a 96-well plate with a cover, medicines, a CAMHB culture medium, 0.9% (w/v) NaCl, bacterial liquid and other objects which are sterilized in advance, (taking 8mg medicines as an example, adding 800 mu l of 0.9% (w/v) NaCl to dissolve and prepare 10mg/ml mother liquor, adding 474.4 mu l of the CAMHB culture medium into 25.6 mu l of mother liquor to obtain the maximum treatment concentration of 512 mu g/ml.)

And a second step of: double dilution method sample addition

Taking A1-12 of 96-well plate as an example, 200 μl of 512 μg/ml of test sample (control antibiotic drug, different antibacterial peptide sample provided by the application, etc.) is added to A12, and 100 μl of CAMHB medium is added to A1-11, respectively. 100 mu l A of solution is taken, added with A11 for blowing and mixing, 100 mu l of solution is sucked out, added with A10 for blowing and mixing, and the operation is continued until after A2 and A2 are blown and mixed, 100 mu l of solution is sucked out and discarded. Ensure that A1 is blank control without any medicine. Then, 100. Mu.l of the bacterial liquid was added to the row gun. Culturing in a bacterial incubator at 37deg.C and 62% humidity for 24 hr.

And a third step of: observation and judgment

After 24h, the 96-well plates were removed. Under the light source, the plate is stably lifted over the top of the head, and bacteria growth conditions of each hole are observed visually through light transmission. The significant growth test of bacteria in the negative control wells (i.e., without the test sample) is only significant. The clear CAMHB status of no apparent colonies was set to the MIC of the group (note: also judged by OD). When single jump holes occur in the minimal medium dilution method, the highest drug concentration that inhibits bacterial growth should be recorded. If a plurality of jump holes appear, the result should not be reported, and the test needs to be repeated.

The MBC assay method is as follows:

(1) Preparation of TSB agar medium: 30g of TSB culture medium dry powder and 15g of agar are weighed, mixed, 1000mL of distilled water is added, and the mixture is sterilized for later use.

(2) Preparation of TSB agar plates: the sterilized TSB culture medium is cooled to about 45 ℃, the culture dish is poured (about 15-20 mL), the dish cover is covered, the culture dish is gently shaken, after the flat plate is cooled and solidified (about 5-10 min is needed), the flat plate is placed upside down, and the dish cover is arranged below, and the dish bottom is arranged above.

(3) And (3) blowing and mixing MIC and 2 times and 4 times of MIC until the maximum concentration of the poriferous bacteria liquid uniformly, sucking 100 mu l of each of the poriferous bacteria liquid out on a TSB agar culture plate which is prepared with corresponding marks in advance, covering a cover, and gently shaking the culture dish back and forth until the bacteria liquid is fully paved on the plate. The bacteria incubator was placed overnight for cultivation. The next day was taken out and the minimum drug concentration in the medium tube corresponding to the inoculum size of <0.1% of the number of colonies growing on each plate was observed, i.e. the Minimum Bactericidal Concentration (MBC) of the drug.

The method for evaluating hemolytic activity was as follows:

healthy rabbit blood (or cynomolgus monkey or human blood) is taken, placed in an conical flask containing glass beads and shaken for 10 minutes, or the blood is stirred with a glass rod to remove fibrinogen, so that defibrinated blood is obtained. Adding 0.9% (w/v) sodium chloride solution about 10 times, shaking, centrifuging at 1000-1500 rpm for 15 min, removing supernatant, and washing the precipitated red blood cells with 0.9% (w/v) sodium chloride solution for 2-3 times until the supernatant does not appear red. The resulting erythrocytes were made into a 2% (w/v) suspension with 0.9% (w/v) sodium chloride solution for testing. 100 μl was added to a round bottom 96 well polystyrene microplate. 100. Mu.L of the sample to be tested, with an initial concentration of 256. Mu.g/mL, was added to each well and diluted in a continuous two-fold gradient. 1% (w/v) triton was used as positive control and DMSO was used as negative control. The mixture was then incubated at 37℃for 1h with shaking of 60 rpm. After incubation, 1000 Xg was centrifuged for 3min and 100. Mu.L of supernatant per well was transferred to a new 96-well plate. If the solution in the test tube is in clear red, the bottom of the tube has no cell residue or a small amount of red blood cell residue, which indicates that hemolysis occurs; if the red blood cells are all sinking, the supernatant is colorless and clear, or the supernatant is colored and clear, no hemolysis occurs. The absorbance at A450nm may be measured to determine the absorbance.

The strain used in the application is as follows:

conventional strains: coli (e.coli) ATCC25922 and enterococcus faecalis (e.faecalis) ATCC29212 standard strains were purchased from ATCC authorities. Staphylococcus aureus (s.aureus) SA113, staphylococcus aureus (s.aureus) CHS101, staphylococcus aureus (s.aureus) YUSA139, staphylococcus aureus (s.aureus) YUSA145, enterococcus faecalis (e.faecalis) 16C166, pseudomonas aeruginosa (p.aeromonas) PA2237, pseudomonas aeruginosa (p.aeromonas) ATCC27853, escherichia coli (e.coli) Eco2242, escherichia coli (e.coli) ATCC25922, klebsiella pneumoniae (k.pneumanniae) K2044, acinetobacter baumannii (a.baumannii) Ab2201, acinetobacter baumannii (a.baumannii) 2202 all deposited at the hospital infectious department of south mountain, at the deposit address: the preservation number is the specific strain number of the peach garden path No. 89 in the southern mountain area of Shenzhen city.

Drug resistant strain: staphylococcus aureus (s.aureus) YUSA132 and staphylococcus aureus (s.aureus) YUSA139 were both deposited in the Shenzhen mountain people nosocomial infectious department with the deposit addresses: the preservation number is the specific strain number of the peach garden path No. 89 in the southern mountain area of Shenzhen city.

Example 1: synthetic antibacterial peptide VKRWKKFRFKWKKWV (WZ-1 SEQ ID NO. 1)

(1) Polypeptide synthesis

Fmoc-Val-OH, fmoc-Trp (Boc) -OH, fmoc-Lys (Boc) -OH, fmoc-Trp (Boc) -OH, fmoc-Lys (Boc) -OH, fmoc-Phe-OH, fmoc-Arg (Pbf) -OH, fmoc-Phe-OH, fmoc-Lys (Boc) -OH, fmoc-Trp (Boc) -OH, fmoc-Arg (Pbf) -OH, fmoc-Lys (Boc) -OH, fmoc-Val-OH were sequentially coupled to a Rink Amide MBHA resin resin (Ji Biochemical Co., ltd., 49006) according to the core peptide sequence of the antimicrobial peptide WZ-1, and after completion of the synthesis, the peptide resin was washed sequentially with DMF, DCM, methanol and dried.

(2) Cleavage, polypeptide purification

The peptide resin obtained in the step (1) was cleaved with a cleavage solution containing TFA (trifluoroacetic acid, CAS#:76-05-1, supplier: shanghai Mecanlin Biochemical Co., ltd.), TIS (triisopropylsilane, CAS#:6485-79-6, supplier: shanghai Mecanlin Biochemical Co., ltd.), EDT (2, 2' - (1, 2-ethylenedioxy) diethyl mercaptan, CAS#:14970-87-7, supplier: shanghai Mecanlin Biochemical Co., ltd.) and H ₂ The volume ratio of O is 91:3:3:3. And filtering out the resin, washing the resin with a small amount of TFA, mixing the filtrates, adding the filtrate into anhydrous diethyl ether to separate out white solid, centrifuging, washing the solid with the anhydrous diethyl ether, and drying in vacuum to obtain WZ-1 crude peptide, purifying the obtained crude peptide by HPLC (purification conditions are as follows), thus obtaining WZ-1 refined peptide, and successfully synthesizing the antibacterial peptide WZ-1 by MS detection conditions are as follows, wherein the detection result is shown in figure 2.

HPLC conditions:

MS conditions:

Instrument	Agilgent-6125B
				Probe:	ESI	Probe bias:	+4.5kV
Nebulizer Gas Flow	1.5L/min	Detector:	1.5kv
				CDL:	-20.0v	T.flow：	0.2ml/min
CDL Temp：	250℃	B.conc.：	50％H ₂ O/50％ACN
				Block Temp：	200℃

example 2: synthetic antibacterial peptide VKRWKKFFRKWKKWV (WZ-3 SEQ ID NO. 2)

Fmoc-Val-OH, fmoc-Trp (Boc) -OH, fmoc-Lys (Boc) -OH, fmoc-Trp (Boc) -OH, fmoc-Lys (Boc) -OH, fmoc-Arg (Pbf) -OH, fmoc-Phe-OH, fmoc-Lys (Boc) -OH, fmoc-Trp (Boc) -OH, fmoc-Arg (Pbf) -OH, fmoc-Lys (Boc) -OH, fmoc-Val-OH) were sequentially coupled to a Rink Amide MBHAresin resin (Ji Biochemical reaction, 49006), and after synthesis, the resin was washed sequentially with DMF, DCM, methanol and dried to give the peptide resin. The peptide resin cleavage, purification and detection steps were the same as in example 1, and HPLC and MS detection results are shown in FIG. 3 and FIG. 4, respectively, and the purity of the prepared WZ-3 was 98.7%.

Example 3: synthesis of N-terminal acetyl-modified antibacterial peptide VKRWKKFFRKWKKWV (hereinafter, referred to as Ac-WZ-3)

Fmoc-Val-OH, fmoc-Trp (Boc) -OH, fmoc-Lys (Boc) -OH, fmoc-Trp (Boc) -OH, fmoc-Lys (Boc) -OH, fmoc-Arg (Pbf) -OH, fmoc-Phe-OH, fmoc-Lys (Boc) -OH, fmoc-Trp (Boc) -OH, fmoc-Arg (Pbf) -OH, fmoc-Lys (Boc) -OH, fmoc-Val-OH) were sequentially coupled to Rink Amide MBHA resin resin (Ji Biochemical reaction (Ji-Chemie, 49006), after completion of the synthesis, acetic anhydride was added, pyridine was acetylated, followed by washing with DMF, DCM, and drying to obtain peptide resin. The purification and detection steps are the same as those of example 1, and the HPLC and MS detection results are shown in FIG. 5 and FIG. 6, respectively, to successfully synthesize the acetyl-modified antibacterial peptide Ac-WZ-3 with the purity of 98.3%.

Example 4: comparison of antibacterial activities of different antibacterial peptides

This example compares the antibacterial properties of the antibacterial peptide WZ-1 with the antibacterial peptide ZY-13 disclosed in patent CN103275190A, demonstrating that the antibacterial peptide provided in example 1 has a superior antibacterial activity.

TABLE 2 comparison of antibacterial Properties of WZ-1 and ZY-13 against different pathogenic bacteria

TABLE 3 comparison of antibacterial effects of WZ-1 and ZY-13 on methicillin-resistant Staphylococcus aureus and methicillin-sensitive Staphylococcus aureus

TABLE 4 comparison of bacteriostatic effects of WZ-1 and ZY-13 on methicillin-resistant Acinetobacter baumannii and methicillin-sensitive Acinetobacter baumannii

TABLE 5 comparison of antibacterial effects of WZ-1 and ZY-13 on methicillin-resistant Lin Feiyan Klebsiella and methicillin-sensitive Klebsiella pneumoniae

TABLE 6 comparison of antibacterial effects of WZ-1 and ZY-13 on methicillin-resistant E.coli and methicillin-sensitive E.coli

TABLE 7 comparison of bacteriostatic effects of WZ-1 and ZY-13 on methicillin-resistant Lin Tonglu and methicillin-sensitive Pseudomonas aeruginosa

As can be seen from tables 2 to 7 above, WZ-1 has antibacterial and bactericidal activities comparable to or superior to ZY-13 against a variety of standard strains of pathogenic bacteria. In addition, from the antibacterial activity data of the system, WZ-1 was comparable to the positive drug ZY-13, both for methicillin-sensitive (MSSA) and drug-resistant Acinetobacter baumannii (MRSA) (Table 4). For other activities derived from other strains in the clinic, antibacterial activity of the antibacterial peptide WZ1 klebsiella pneumoniae (table 5), escherichia coli (table 6), pseudomonas aeruginosa (table 7) was superior to ZY13 or comparable thereto in whole.

Example 5

This example refers to the synthetic method of example 1, and compares the physicochemical parameters and antibacterial activity of these antibacterial peptides with those obtained in examples 1 and 3, and compares the antibacterial properties of the antibacterial peptides as disclosed in CN103275190a, the antibacterial peptides ZY-13 disclosed in patent WO2016201972A1, BF-30 (IND in 2018 for bacterial vaginitis treatment, effervescent tablets), ampicillin (Ampicillin), vancomycin (Vancomycin) and Gentamicin, demonstrating that the antibacterial peptides provided in examples 1 and 3 have better antibacterial activity.

TABLE 8 alignment of amino acid sequences and physicochemical parameters of different antibacterial peptides

Sequence number	ID	peptides	PI	#	Net Charge	H	HM
								1	WZ-1	VKRWKKFRFKWKKWV-NH2	12.1	15	8	0.321	0.612
2	WZ-3	VKRWKKFFRKWKKWV-NH2	12.1	15	8	0.321	0.889
								3	WZ-15	VKRFKKFFRKLKKSV-NH2	12.1	15	8	0.101	0.78
4	WZ-17	IKRFKKFRWKLKKWV-NH2	12.1	15	8	0.323	0.528
								5	WZ-18	IKRFKKFKWKLKKWI-NH2	11.5	15	8	0.363	0.562

TABLE 9 comparison of antibacterial Activity of different antibacterial peptides

As can be seen from tables 8 and 9 above, the antibacterial peptides provided in examples 1 and 3 have superior antibacterial activity to other antibacterial peptides having similar amino acid sequences, the three antibacterial peptides reported, and the three antibiotics.

Example 6

In this example, the antibacterial peptide obtained in example 3 and the antibacterial peptide prepared from D-type amino acid according to the preparation method of reference example 2 are compared with the antibacterial activity of two clinical candidate drugs PL-5 (CAS#: 850761-47-6, in clinical II-III, for diabetic foot ulcers, spray) and PL-18 (patent CN102219831B, for bacterial/fungal vaginitis treatment, suppository), and it is demonstrated that the N-terminal modified antibacterial peptide provided by the present application and the antibacterial peptide synthesized from D-type amino acid have better antibacterial activity.

Table 10 comparison of antibacterial activity of acetyl modified different antibacterial peptides

In addition, the N-terminal modified acetyl is replaced by other modified functional groups, and the N-terminal modified acetyl has antibacterial activity equivalent to or better than that of the acetyl.

Example 7: evaluation of hemolytic Activity

According to the hemolytic activity evaluation method, the hemolytic activity experiments of the antibacterial peptides WZ-1, WZ-3, AC-WZ-3 and ZY-13 obtained in the above examples are carried out, and the results are shown in FIG. 7, and it can be seen that the antibacterial peptides WZ-1, WZ-3 and AC-WZ-3 provided by the application have no hemolytic toxicity at the highest concentration of 256 mug/ml, and the antibacterial peptides provided in the above examples are proved to be safe and effective.

Although specific embodiments of the application have been described in detail, those skilled in the art will appreciate. Numerous modifications and substitutions of details are possible in light of all the teachings disclosed, and such modifications are contemplated as falling within the scope of the present application.

Claims

1. An antibacterial peptide, characterized in that the antibacterial peptide has the amino acid sequence VKRWKKFX ₁ X ₂ KWKKWV, wherein X ₁ And X ₂ Are each selected from amino acids having aromatic side chains or amino acids having basic side chains.

2. The antimicrobial peptide of claim 1, wherein X is ₁ And X ₂ Respectively selected from phenylalanine or arginine.

3. The antimicrobial peptide according to claim 1 or 2, wherein the antimicrobial peptide has an amino acid sequence shown in any one of SEQ ID No.1 or 2.

4. The antibacterial peptide according to claim 3, wherein the antibacterial peptide contains a modified functional group at the N-terminus, the modified functional group being selected from the group consisting of 5-isoxazole-5-carbonyl, acetyl, 2- (1-imidazolyl) acetyl, benzoyl, decacarbonyl, 2-morpholinoacetyl, pyrazinyl, dodecanyl, p-toluenesulfonyl and 2-methylthiazole-5-carbonyl.

5. The antimicrobial peptide of claim 4, wherein the modified antimicrobial peptide comprises at least one D-type or β -type amino acid.

6. The method for producing an antibacterial peptide according to any one of claims 1 to 3, wherein the amino acid having a side chain protecting group is sequentially coupled according to the amino acid sequence by a solid phase synthesis or liquid phase synthesis method, and then the side chain protecting group is removed, extracted and purified sequentially to obtain the antibacterial peptide.

7. The method according to claim 6, further comprising the step of subjecting the solid phase synthetic antimicrobial peptide to N-terminal modification using a functional group selected from the group consisting of 5-isoxazole-5 formyl, acetyl, 2- (1-imidazolyl) acetyl, benzoyl, decanoyl, 2-morpholinoacetyl, pyrazinecanoyl, dodecanoyl, p-toluenesulfonyl and 2-methylthiazole-5-formyl.

8. The method according to claim 6 or 7, wherein at least one of the amino acids used for solid phase synthesis is a D-form or a beta-form amino acid.

9. Use of the antibacterial peptide according to any one of claims 1 to 5 or the antibacterial peptide obtained by the preparation method according to any one of claims 6 to 8 for the preparation of antibacterial drugs, anti-infective drugs, wound repair products, acne treatment drugs, radiodermatitis control drugs, preservatives, animal feeds or cosmetic precursors.

10. An antibacterial pharmaceutical preparation, characterized in that the antibacterial pharmaceutical preparation contains the antibacterial peptide according to any one of claims 1 to 5 or the antibacterial peptide prepared by the preparation method according to any one of claims 6 to 8.

11. The antibacterial pharmaceutical formulation according to claim 10, wherein the effective dose of the antibacterial peptide is 0.01-512 μg/ml, preferably 0.125-256 μg/ml.

12. An antimicrobial pharmaceutical formulation according to claim 10 or 11, wherein the pathogenic microbial species of antimicrobial action comprise bacteria and/or fungi;

13. The antimicrobial pharmaceutical formulation of claim 12, wherein the pathogenic microorganism is resistant and the antibiotic-resistant drug class comprises at least one of beta-lactams, cephalosporins, aminoglycosides, macrolides, tetracyclines, fluoroquinolones, sulfonamides, or rifampin.

14. The antibacterial pharmaceutical formulation according to claim 13, wherein the dosage form of the antibacterial pharmaceutical formulation comprises an oral formulation, an external formulation or an injection;

the oral preparation comprises granules, tablets, paste or oral solution;

the external preparation comprises ointment, gel, suppository, medicated bath liquid, hoof bath liquid or spray.